Core Insights - The company, Bibet, announced the results of its new stock issuance, with online investors subscribing to 21.5392 million shares, amounting to 383 million yuan, while offline investors fully subscribed [2][3] - The total issuance was 90 million shares at a price of 17.78 yuan per share, with online subscriptions accounting for 24% of the total issuance [3] Online Subscription Details - Online subscription quantity: 21.5392 million shares - Online subscription amount: 383 million yuan - Online abandonment quantity: 60,800 shares, with an abandonment rate of 0.281264% and an abandonment amount of 1.0802 million yuan [2][3] - Final online issuance quantity: 21.6 million shares, with a final winning rate of 0.04772481% [3] Offline Subscription Details - Offline subscription quantity: 50.4 million shares - Offline subscription amount: 896.112 million yuan - No abandonment from offline investors, with all shares fully subscribed [2][3] Company Focus - Bibet specializes in the treatment of major diseases such as tumors, autoimmune diseases, and metabolic diseases, with core products classified as Class 1 new chemical drugs [3] - The main therapeutic areas include malignant lymphoma, breast cancer, non-small cell lung cancer, ovarian cancer, psoriasis, and diabetes with non-alcoholic fatty liver disease [3]

Core Viewpoint - The company, Bibet, is set to launch its public offering with a total share capital of 360 million shares, aiming to issue 90 million shares, which represents 20% of the post-issue total share capital, at a price of 17.78 yuan per share [1] Company Overview - Bibet focuses on the treatment of major diseases such as tumors, autoimmune diseases, and metabolic diseases, with core products classified as Class 1 new chemical drugs [1] - The main therapeutic areas include malignant lymphoma, breast cancer, non-small cell lung cancer, ovarian cancer, psoriasis, and diabetes-related non-alcoholic fatty liver disease [1] Public Offering Details - The public offering will consist of 90 million shares, with 14.4 million shares available for online subscription [1] - The subscription code is 787759, and the maximum subscription limit for a single account is 14,000 shares, requiring a market value of 140,000 yuan in the Shanghai market for the highest subscription [1] - The announcement of the winning numbers and payment date is set for October 21, 2025 [1] Fundraising Allocation - The funds raised will be allocated as follows: - New drug research and development project: 94,912.34 thousand yuan - Construction of the Qingyuan R&D center and formulation industrialization base: 55,548.57 thousand yuan - Supplementing working capital: 50,000.00 thousand yuan [1] Financial Performance - The company reported total assets of 33,247.71 thousand yuan in 2024, down from 44,187.25 thousand yuan in 2023 and 58,721.68 thousand yuan in 2022 [2] - Net assets decreased to 29,022.01 thousand yuan in 2024 from 31,811.96 thousand yuan in 2023 and 46,833.49 thousand yuan in 2022 [2] - The company has not generated any operating revenue, with a net loss attributable to shareholders of 5,599.83 thousand yuan in 2024, an improvement from a loss of 17,275.51 thousand yuan in 2023 and 18,833.88 thousand yuan in 2022 [2] - Research and development expenses were 12,028.74 thousand yuan in 2024, down from 15,765.12 thousand yuan in 2023 and 16,674.07 thousand yuan in 2022 [2]